Am happy CYDY decided to do the CD17 trial. May or may not lead to any sort of approval or revenues. It just seems there is more to be learned about delivery, dosage, timing,etc... Plus this sub group (elderly) would likely be a part of trials for other indications & might pose a challenge in those trials as well. Knowledge gained now in CD17 could be valuable down the road. Idk.